A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

ClinicalTrials.gov ID: NCT03234712

Public ClinicalTrials.gov record NCT03234712. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 12, 2026, 8:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Study identification

NCT ID: NCT03234712
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: AbbVie; Industry
Enrollment: 62 participants

Conditions and interventions

Conditions

Advanced Solid Tumors Cancer

Interventions

ABBV-321 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 9, 2017
Primary completion: Apr 13, 2021
Completion: Apr 13, 2021
Last update posted: May 5, 2021

2017 – 2021

United States locations

U.S. sites: 14
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Highlands Oncology Group /ID# 166132	Springdale	Arkansas	72762	—
The Angeles Clinic and Researc /ID# 166133	Los Angeles	California	90025	—
University of California, Davis Comprehensive Cancer Center /ID# 215012	Sacramento	California	95817	—
Northwestern University Feinberg School of Medicine /ID# 165191	Chicago	Illinois	60611-2927	—
University of Chicago /ID# 166064	Chicago	Illinois	60637	—
Northshore University Health System Dermatology Clinical Trials Unit /ID# 201095	Skokie	Illinois	60077	—
University of Kentucky Markey Cancer Center /ID# 217665	Lexington	Kentucky	40536-7001	—
Dana-Farber Cancer Institute /ID# 212920	Boston	Massachusetts	02215	—
Washington University-School of Medicine /ID# 214955	St Louis	Missouri	63110	—
Columbia Univ Medical Center /ID# 167184	New York	New York	10032-3725	—
Stony Brook University Hospital /ID# 216976	Stony Brook	New York	11794-8183	—
Duke University Medical Center /ID# 166135	Durham	North Carolina	27710-3000	—
Lifespan Cancer Institute at Rhode Island Hospital /ID# 168600	Providence	Rhode Island	02903-4923	—
South Texas Accelerated Research Therapeutics /ID# 166134	San Antonio	Texas	78229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03234712, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 5, 2021 · Synced May 12, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03234712 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →